Latest News
Conference Coverage
Carpal tunnel syndrome may flag cardiac amyloidosis in elderly
DALLAS – Tenosynovial amyloidosis signaled cardiac involvement in some patients undergoing carpal tunnel release surgery.
Feature
VIDEO: Keep index of suspicion high for groups at risk of suicide and substance abuse
WASHINGTON – Suicides increased by 25% during 2000-2015, and opioid-related deaths have quadrupled since 1999, according to the most recent data...
Feature
Opioid deaths and suicides – twin tragedies that need a community-wide response
The health care community is struggling to create a unified plan to overcome the community damage done by the overlapping rise in suicide and...
From the Journals
Dabigatran, rivaroxaban linked to slight increase in GI bleeding risk
Overall, the risk of major bleeds associated with NOACs was similar to the risk with conventional anticoagulants.
Feature
Ruling: Apologies can’t be used against doctors in court
The Ohio Supreme Court has ruled that apologies by physicians that include an admission of fault cannot be used against them in court, upholding a...
Latest News
HHS Secretary resigns amid flight criticism
Tom Price, MD, resigned his post following scrutiny over his use of private charter planes at taxpayers’ expense.
From the Journals
Personality changes may not occur before Alzheimer’s onset
Study authors speculate that self-reported personality changes might not be as reliable as informant report.
Conference Coverage
ADHD meds don’t raise seizure risk in epilepsy patients
Seizure risk was actually significantly lower for individual patients while on ADHD medication.
From the Journals
Deep brain stimulation shows promise in treating Tourette syndrome
While deep brain stimulation is not approved for Tourette syndrome in the United States, it shows promise as a treatment option.
Feature
Proposed MACRA participation threshold gets mixed reviews
Some groups praised the expanded exemption threshold, while others said it would keep too many physicians out.
From the Journals
Caffeine offers no perks for Parkinson’s patients
The findings from a 6-month, double-blind, multicenter, placebo-controlled trial contradict those from an earlier 6-week pilot trial.